Donate
T1International Statement on Lilly's "authorized generic" Humalog

T1International Statement on Lilly's "authorized generic" Humalog

Facebook Google LinkedIn Twitter

Patient-led activism is working. Today Eli Lilly announced that in response to criticism of high prices, the company will sell a version of Humalog insulin for half price. We are pleased to see this result after relentless efforts by non-pharma funded patient advocates to ensure the list price of insulin goes down.

While $137.35 is an improvement, it's still an unaffordable price for so many, considering most people need at least 2 vials each month. Humalog increased 585% between 2001 and 2015 and we have no guarantee that this "half-price" insulin won't double again in the near future. An estimate for the cost to produce a vial of analogue insulin is about $6 at most, which means Eli Lilly and the other insulin manufacturers could make this life saving drug even more affordable while still making enormous profits. Eli Lilly, Novo Nordisk and Sanofi can and should be offering genuinely affordable prices to all who need insulin to survive.

T1International and those in the #insulin4all movement will remain vigilant. This is certainly only the beginning, and a small step towards the change needed in pricing for people with type 1 diabetes. This does not get Eli Lilly off the hook for their price-gouging and it shows us that they have the power to set a price that is truly affordable at any time.

Make no mistake - by Eli Lilly’s own admission the company is only reacting to outside pressure. We must still fight for transparency legislation and ultimately price controls to ensure that prices go down and stay down. That is what T1International and patient advocates across the USA will continue to fight for.

Related posts:

Reminder: Eli Lilly Has Been Exploiting T1Ds Since 1922

Reminder: Eli Lilly Has Been Exploiting T1Ds Since 1922

The “business of diabetes” did not spontaneously emerge mid-century. Corporate stakeholders found underhanded ways to profit from diabetic lives before most affected individuals had even obtained their first injection. And now that Congress is investigating insulin manufacturers, it is important to acknowledge the full scope of their involvement. Read more

Nicole Smith-Holt Statement on Eli Lilly Helpline Announcement

Nicole Smith-Holt Statement on Eli Lilly Helpline Announcement

I vow to continue to fight for the rights and lives of all people with diabetes. I am doing all this in honor of my son, Alec Raeshawn Smith. I invite Lilly to work with me and non-industry funded organizations like T1International so that we can find real solutions to ensure #insulin4all. Mr. Mason, I am still waiting to hear from you. Read more

My Journey to Eli Lilly HQ for Answers

My Journey to Eli Lilly HQ for Answers

I was very nervous before going to confront the top executives of Eli Lilly and Company. But I was determined to tell them Alec’s story. They needed to hear from me what their insulin prices did to Alec, and are still doing to others. Read more

Taking a Stand at Eli Lilly Headquarters

Taking a Stand at Eli Lilly Headquarters

I joined dozens of people impacted by the rising cost of insulin in the USA in protest of those prices in front of Eli Lilly headquarters in Indianapolis, Indiana. Some had traveled many hours to join the protest, but one thing was made clear, we wanted to ensure that Eli Lilly heard our voices. We were passionate in our outcry for change and jointly understood that not saying anything is simply not an option.
Read more

Eli Lilly and Novo Nordisk: More Empty Promises

Eli Lilly and Novo Nordisk: More Empty Promises

Outrage at soaring insulin prices in the USA has been increasing. More patients and families are speaking out against unaffordable costs for life-saving medication than ever before. In response, two of the 'Big Three' insulin makers (who control over 90% of the insulin market) have recently made moves to combat this anger. Read more